MDM2 and cancer: Cisplatin treatment of cancer cells leads to p53 activation and its stabilisation by phosphorylation at the Ser15 and/or Ser20 sites, which inhibit the p53 association with E3 ubiquitin ligase mouse double minute 2 (Mdm2).